Busy IPO week winds down as two more biotechs — and one looking to improve clinical trials — file for public debuts
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Two more biotech companies — and one that’s committed to supporting clinical research — filed for IPOs just before the long weekend.
Nobel laureate Jennifer Doudna’s Caribou Biosciences is penciling in a $100 million raise to support its off-the-shelf CAR-T therapies, one of which is making its way through a Phase I study in B-cell non-Hodgkin lymphoma. Also looking for a $100 million raise is WCG Clinical Services, which established itself as an ally to biopharma companies and CROs back in 2012. The company offers planning, patient engagement, and ethical review services, and says it was behind more than 723 Covid-19 trials. Meanwhile, transpacific biotech Brii Biosciences is looking for its own ticker on the Hong Kong Stock Exchange, and says it’ll use the funds across its broad infectious disease and CNS pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.